Akihiko Koyama

Eisai, Inc. - Eisai, Inc. - United States

Woodcliff Lake, NJ

United States

SCHOLARLY PAPERS

1

DOWNLOADS

44

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with BAN2401, an Anti-Aβ Protofibril Antibody

Number of pages: 40 Posted: 29 Sep 2020
Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai Ltd., BioArctic AB, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Berry Consultants, LLC, Berry Consultants, LLC, Eisai Ltd., Eisai, Inc. - Eisai, Inc. - United States and Cleveland Clinic - Lou Ruvo Center for Brain Health
Downloads 44 (482,758)

Abstract:

Loading...

Alzheimer's disease, BAN2401, clinical trial, biomarker, ADCOMS, amyloid PET, neurofilament light, neurogranin, p-tau